Skip to content

URMC Response to CrowdStrike Software Issue

Saturday, July 20: All UR Medicine facilities are open as scheduled and providing safe patient care, with a goal to return all clinical services to full efficiency by early next week.

Patients: click here for more information. Faculty/Staff: click here for information.

Anton Pjetur Porsteinsson, M.D.

Anton Pjetur Porsteinsson, M.D.

Mental Health and Wellness

4.9 out of 5 stars
UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients


About Me

Dr. Porsteinsson is the Director of the University of Rochester Alzheimer's Disease Care, Research and Education Program (AD-CARE). In addition, he is the first William B. and Sheila Konar Professor of Psychiatry at the University of Rochester, School of Medicine and Dentistry. In 1987, he receive...
Dr. Porsteinsson is the Director of the University of Rochester Alzheimer's Disease Care, Research and Education Program (AD-CARE). In addition, he is the first William B. and Sheila Konar Professor of Psychiatry at the University of Rochester, School of Medicine and Dentistry. In 1987, he received his MD degree from the University of Iceland School of Medicine and came to the University of Rochester in 1989, where he completed his internship and residency. He is Board certified in Psychiatry, with added qualifications in Geriatric Psychiatry.
Dr. Porsteinsson has devoted his career to the care and study of individuals with memory disorders. He participates in the University of Rochester Memory Care Program, which serves a population with memory disorders. Internationally recognized in clinical research and considered one of the leading experts in Alzheimer's disease and dementia, his interests lie in biomarkers, imaging, and novel pharmacologic agents in the treatment of Alzheimer's disease and other dementias, both in terms of cognitive loss and behavioral disturbances. He is a leading investigator for many prominent national Alzheimer's prevention and treatment trials and has conducted major clinical trials with cognitive enhancers and course stabilizing agents in dementia, as well as psychotropics for behavioral changes associated with dementia. Dr. Porsteinsson is the author and collaborator of hundreds of research publications and serves as site principal investigator for research grants from the National Institutes of Health and other leading funders.

Faculty Appointments

Professor - Department of Psychiatry, Geriatric/Psychiatry (SMD)

William and Sheila Konar Endowed Professorship - Department of Psychiatry (SMD)

Professor - Department of Medicine, Geriatrics/Aging (SMD) - Joint

Professor - Department of Neurology, Memory Care (SMD) - Joint

Professor - Department of Neuroscience (SMD) - Joint


Residency & Fellowship

Residency, Psychiatry, University of Rochester Medical Center. 1990 - 1993

Internship, University of Rochester Medical Center. 1989 - 1990

Internship, University of Iceland, Reykjavik. 1987 - 1989


Listed in Editions of America's Top Doctors. 2012

Listed in editions of Distinguished Professionals. 2010

Listed in editions of The Global Directory of Who's Who. 2010

Dr. John Baum Award, University of Rochester School of Medicine and Dentistry. 2009

Listed in editions of Who's Who in America. 2007

Summer Research Institute Fellowship. 1999

The Helga Jonsdottir and Sigurlidi Kristjansson Memorial Award. 1997

Carl Albert Jaenike Award. 1993

Residents' Recognition Award. 1993

Consultation-Liaison Award. 1992

Thorvaldur Thoroddsens Memorial Award. 1981

P.O. Christensens Memorial Award. 1981


Research Lab


Journal Articles

Insula and Inferior Frontal Gyrus' Activations Protect Memory Performance Against Alzheimer's Pathology in Old Age. .

Lin F, Ren P, Lo Y, Chapman B, Jacobs A, Baran T, Porsteinsson AP, Foxe J.

J Alzheimers Dis. 2017; 55(2): 669-678.

The Cingulate Cortex of Older Adults with Excellent Memory Capacity

Lin F, Ren P, Mapstone M, Meyers S, Porsteinsson AP, Baran TM.

Cortex. 2017; : 83-92.

Changes in Neuropsychiatric Inventory associated with semagestat treatment of Alzheimer's disease.

Rosenberg PB; Lanctot KL; Herrmann N; Mintzer JE; Porsteinsson AP; Sun X; Raman R.

J Alzheimers Disease. 2016; 54(1): 373-81.

Cognitive and Neural Effects of Vision-Based Speed of Processing Training in Older Adults with Mild Cognitive Impairment: A pilot study

Lin F, Heffner K, Tivarus M, Ren P, Brasch J, Chen D, Mapstone M, Porsteinsson AP, and Tadin D.

J Am Geriatr Soc. 2016; 64(6): 1293-8.

Citalopram for the Treatment of Agitation in Alzheimer's Dementia: Genetic Influences.

Peters ME, Vaidya V, Drye LT, Devanand DP, Mintzer JE, Pollock BG, Porsteinsson AP, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, MD8, Lyketsos CG, and Avramopoulos D: For the CitAD Research Group.

J Geriatr Psychiatry Neurol. 2016; 29(2): 59-64.

ERP C250 Shows the Elderly (Cognitively Normal, Alzheimer's Disease) Store More Stimuli in Short-Term Memory than Young Adults Do.

Chapman R, Gardner MN, Mapstone M, Klorman R, Porsteinsson AP, Dupree HM, Antonsdottir IM, Kamalyan L.

Clinical Neurophysiology 127. 2016; : 2423–2435.

Trajectories of neuropsychiatric symptoms and cognitive decline in mild cognitive impairment.

David N, Lin F, Porsteinsson AP.

Am J Geriatr Psychiatry. 2016; 24(1): 70-80.

Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence from the CitAD Study

Leonpacher A, Peters ME, Drye LT, Makino KM, Newell J, Devanand DP, Frangakis C, Mintzer JE, Munro CA, Pollock BG, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, Porsteinsson AP: For the CitAD Research Group.

Am J Psychiatry. 2016; 173(5): 473-80.

Heterogeneity of Treatment Response to Citalopram for Alzheimer Disease Patients with Aggression or Agitation: The CitAD Randomized Clinical Trial.

Schneider LS, Frangakis C, Drye LT, Devanand DP, Marano C, Mintzer JE, Mulsant BH, Munro CA, Newell JA, Pawluczyk S, Pelton G, Pollock BG, Porsteinsson AP, Rabins PV, Rein L, Rosenberg PB, Shade DM, Weintraub D, Yesavage J, and Lyketsos CG, for the CitAD Research Group.

Am J Psychiatry. 2016; 173(5): 465-72.

Dazed and Confused - Medical Cannabis in Alzheimer's Disease.

Antonsdottir IM, Makino KM, Porsteinsson AP.

Am J Geriatr Psychiatry. 2016; 24(11): 1004-06.

Clinical Benefit of Tramiprosate in AD are associated with higher number of APOE4 alleles: "The Gene-Dose Effect"

Abushakra S, Porsteinsson AP, Vellas B, et al.

J Prev Alz Dis. 2016; 3(4): 219-228.

Change in Agitation in Alzheimer's disease in the placebo arm of a 9-week controlled trial.

Rosenberg PB; Drye LT; Porsteinsson AP; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Schneider LS; Shade DM; Weintraub D; Newell J; Yesavage J; and Lyketsos CG, for the CitAD Research Group.

Int Psychogeriatric. 2015; 27(12): 2059-67.

Time to response to citalopram treatment for agitation in Alzheimer's disease

Weintraub D, Drye LT, Porsteinsson AP, Rosenberg PB, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Schneider LS, Shade DM, Yesavage J, and Lyketsos CG, for the CitAD Research Group.

Am J Geriatr Psychiatry. 2015; 23(11): 1127-33.

Dextromethorphan/Quinidine (DM/Q) for Agitation/Aggression in Alzheimer's Disease Dementia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Cummings J, Lyketsos CG, Peskind ER, Porsteinsson AP, Mintzer JE, Scharre DW, De La Gandara JE, Agronin M, Davis CS, Nguyen U, Shin P, Tariot PN, and Siffert J, for the 12-AVR-131 Study Group.

JAMA. 2015; 314(12): 1242-1254.

Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders.

Profenno LA, Porsteinsson AP, Faraone SV

Biological psychiatry.. 2010 March 1567 (6):505-12. Epub 04/09/2009.

Predicting Conversion from Mild Cognitive Impairment to Alzheimer's Disease Using Neuropsychological Tests and Multivariate Methods.

Chapman, AP.; Mapstone, M.; McCrary, J.W.; Gardner, M.N.; Porsteinsson, A.P.

Journal of Clinical and Experimental Neuropsychology. 2010; 13: 1-13.

Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.

Sevigny JJ, Ryan JM, van Dyck CH, Peng Y, Lines CR, Nessly ML,

Neurology.. 2008 November 1871 (21):1702-8. Epub 1900 01 01.

Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.

, Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M

Archives of neurology.. 2008 July 65 (7):896-905. Epub 05/12/2008.

A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease.

Streim JE, Porsteinsson AP, Breder CD, Swanink R, Marcus R, McQuade R, Carson WH

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.. 2008 July 16 (7):537-50. Epub 1900 01 01.

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.

Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT,

Current Alzheimer research.. 2008 February 5 (1):83-9. Epub 1900 01 01.

Memantine in the treatment of mild-to-moderate Alzheimer's disease.

Cosman KM, Boyle LL, Porsteinsson AP

Expert opinion on pharmacotherapy.. 2007 February 8 (2):203-14. Epub 1900 01 01.

Design of Depression in Alzheimer's Disease Study-2.

Martin BK, Frangakis CE, Rosenberg PB, Mintzer JE, Katz IR, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Niederehe G, Lyketsos CG

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.. 2006 November 14 (11):920-30. Epub 1900 01 01.

Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.

Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, Zoulnouni P, Galvin JE, Holtzman DM, Knopman DS, Satterwhite J, Gonzales C, Dean RA, May PC

Neurology.. 2006 February 2866 (4):602-4. Epub 1900 01 01.

Divalproex sodium for the treatment of behavioural problems associated with dementia in the elderly.

Porsteinsson AP

Drugs & aging.. 2006 23 (11):877-86. Epub 1900 01 01.

A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer's disease.

Profenno LA, Jakimovich L, Holt CJ, Porsteinsson A, Tariot PN

Current Alzheimer research.. 2005 December 2 (5):553-8. Epub 1900 01 01.

Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial.

Tariot PN, Raman R, Jakimovich L, Schneider L, Porsteinsson A, Thomas R, Mintzer J, Brenner R, Schafer K, Thal L, ,

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.. 2005 November 13 (11):942-9. Epub 1900 01 01.

Clinical application of operationalized criteria for 'Depression of Alzheimer's Disease'.

Rosenberg PB, Onyike CU, Katz IR, Porsteinsson AP, Mintzer JE, Schneider LS, Rabins PV, Meinert CL, Martin BK, Lyketsos CG,

International journal of geriatric psychiatry.. 2005 February 20 (2):119-27. Epub 1900 01 01.

Memantine – A Novel Therapeutic Option for Alzheimer's Disease.

Porsteinsson AP; Ismail MS.

Today's Therapeutic Trends. 2004; 22(1): 17-28.

Choosing treatment for Alzheimer's patients and their caregivers.

Schneider LS, Porsteinsson AP, Peskin ER, Pfeiffer EA

Geriatrics.. 2003 August 58 Suppl 1 :3-18, 23; quiz 19-22. Epub 1900 01 01.

Valproate therapy for agitation in dementia: open-label extension of a double-blind trial.

Porsteinsson AP, Tariot PN, Jakimovich LJ, Kowalski N, Holt C, Erb R, Cox C

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.. 2003 11 (4):434-40. Epub 1900 01 01.

Dementia management: regulations, rules, and research.

Tune LE, Porsteinsson A, Weinberg A

Journal of the American Medical Directors Association.. 2003 4 (4 Suppl):H13-6. Epub 1900 01 01.

Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales.

Tariot PN, Loy R, Ryan JM, Porsteinsson A, Ismail S

Advanced drug delivery reviews.. 2002 December 754 (12):1567-77. Epub 1900 01 01.

Interactive grand rounds: mood stabilizers in dementia.

Nelson JC, Tune LE, Daiello LA, Porsteinsson A

Geriatrics.. 2002 September 57 (9):suppl 2-5. Epub 1900 01 01.

Pharmacologic therapy for behavioral symptoms of Alzheimer's disease.

Tariot PN, Ryan JM, Porsteinsson AP, Loy R, Schneider LS

Clinics in geriatric medicine.. 2001 May 17 (2):359-76. Epub 1900 01 01.

Second generation anticonvulsant medications: their use in children.

Noviasky JA, Porsteinsson AP, Lee YH

The Journal of school nursing : the official publication of the National Association of School Nurses.. 2001 April 17 (2):103-11. Epub 1900 01 01.

Placebo-controlled study of divalproex sodium for agitation in dementia.

Porsteinsson AP, Tariot PN, Erb R, Cox C, Smith E, Jakimovich L, Noviasky J, Kowalski N, Holt CJ, Irvine C

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.. 2001 9 (1):58-66. Epub 1900 01 01.

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C

Neurology.. 2000 June 2754 (12):2269-76. Epub 1900 01 01.

Reconsidering the DSM-IV diagnoses of Alzheimer's disease: behavioral and psychological symptoms in patients

Caine ED; Porsteinsson A; Lyness JM; First M;.

International Psychogeriatrics. 2000; 12(1): 23-27.

Mood Disturbances in Alzheimer's Disease.

Porsteinsson AP, Tariot PN, Schneider LS

Seminars in clinical neuropsychiatry.. 1997 October 2 (4):265-275. Epub 1900 01 01.

Treating Alzheimer's disease. Pharmacologic options now and in the near future.

Tariot PN, Schneider L, Porsteinsson AP

Postgraduate medicine.. 1997 June 101 (6):73-6, 81, 84 passim. Epub 1900 01 01.

Suicide and Alcoholism: Distinguishing Alcoholics with and without Comorbid Drug Abuse.

Porsteinsson, A.; Duberstein, P.; Conwell, Y.; Cox, C.; Forbes, N.; Caine, E.D.

American Journal of Addictions. 1997; 6: 304-310.

An open trial of valproate for agitation in geriatric neuropsychiatric disorders.

Porsteinsson AP, Tariot PN, Erb R, Gaile S

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.. 1997 5 (4):344-51. Epub 1900 01 01.

Suicide and alcoholism. Distinguishing alcoholic patients with and without comorbid drug abuse.

Porsteinsson A, Duberstein PR, Conwell Y, Cox C, Forbes N, Caine ED

The American journal on addictions. 1997 6 (4):304-10. Epub 1900 01 01.

Treatment of agitation in dementia.

Tariot P, Gaile SE, Castelli NA, Porsteinsson AP

New directions for mental health services. 1997 (76):109-23. Epub 1900 01 01.

Thyroid evaluation of hospitalized psychiatric patients: the role of TSH screening for thyroid dysfunction.

Woolf PD, Nichols D, Porsteinsson A, Boulay R

Thyroid : official journal of the American Thyroid Association.. 1996 October 6 (5):451-6. Epub 1900 01 01.

Measurement of Behavioral Disturbance in Chronic Care Populations.

Tariot PN; Teri L; Porsteinsson A; Weiner;.

Journal of Mental Health Aging. 1996; 2(3): 213-229.

Atomoxetine Augmentation of Cholinesterase Inhibitor Therapy in Alzheimer's Disease.

Mohs RC, Shiovitz TM, Tariot PN, Porsteinsson AP, Baker KD, Feldman PD.

Neurology. .

Depression and Cognitive Disorders in Older Primary Care Patients.

Boyle LL; Porsteinsson AP; Cui X; King DA; Lyness JM.

Journal of Clinical Psychiatry. .


Neurodegenerative Dementias (1999)

Chapter: Nursing Homes and Long Term Care.

Authors: Porsteinsson, AP; Tariot, PN;

Publisher: McGraw-Hill Companies, New York 1999

Measurement in Elderly Chronic Care Populations (1997)

Chapter: Measurement of Behavioral Disturbances in Chronic Care Populations.

Authors: Tariot, PN; Porsteinsson, AP; Teri L; Weiner MF;

Publisher: Springer Publishing Company, Incorporated, New York 1997

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.


During this visit, did this provider spend enough time with you?

4.8 stars

During this visit, did this provider show respect for what you had to say?

4.9 stars

During this visit, did this provider give you easy to understand information about these health questions or concerns?

5.0 stars

During this visit, did this provider listen carefully to you?

4.9 stars

During this visit, did this provider explain things in a way that was easy to understand?

4.8 stars

Patient Comments

5.0 stars

Dr. Anton is one of the best doctors of any specialty I have ever encountered.

Apr 29, 2024

5.0 stars

Glad to have Dr P as my provider

Apr 28, 2024

5.0 stars

[...] If I were to recommend treatment for someone else, I would refer them to the office not to this provider.

Apr 15, 2024

5.0 stars


Sep 05, 2023

5.0 stars

We/you are so blessed & fortunate to have Dr. Anton as a provider. Without equal to any provider I've worked with professionally, or experienced as a provider in my 60 years of nursing practice!!.

Aug 10, 2023

5.0 stars

I have recommended him several times. I believe he is the best specialist for dementia in town.

Aug 09, 2023

5.0 stars

Dr. P is one of the best specialists I've seen. He's my neurologist for life!

Aug 02, 2023

5.0 stars

Good experience.

Jul 13, 2023

5.0 stars

He is a great dr.

Jul 12, 2023

5.0 stars

I think Dr. P is world class. He and his team are helping us through a very difficult time.

Feb 21, 2022


This will be a long treatment issue and provider was very good at explaining that.

Feb 02, 2022